Akorn Inc (AKRX) 34.93 $AKRX
Stocks Sag In Rising Trade; Archer Daniels And Avis Rise
at Investor's Business Daily - Tue Aug 05, 9:39AM CDT
Stocks stubbornly held their opening losses Tuesday, despite some strong factory orders and service-sector data. The Nasdaq and S&P 500 dipped 0.5% each. The Dow Jones industrial average slipped 3%. Small caps lagged the pack, with the Russell 2000...
Actavis Guidance Disappoints; Akorn Beats And Raises
at Investor's Business Daily - Tue Aug 05, 9:29AM CDT
Specialty drugmakers and IBD 50 stocks Actavis (ACT) and Akorn were headed in opposite directions in the stock market today after the companies reported their second-quarter earnings and updated their guidance. Actavis' earnings rose 70% over the...
Stock Futures Grope Lower; Gannett Surges On Plan To Split
at Investor's Business Daily - Tue Aug 05, 8:02AM CDT
Stock futures ticked lower early Tuesday as a weak services sector report out of China rattled China-based stocks in the U.S. Dow futures dived 66.3 points below fair market value and were still dropping. Nasdaq 100 futures were off a sharp 19.3...
Why Akorn (AKRX) Stock Is Advancing Today
at The Street - Tue Aug 05, 7:26AM CDT
Shares of Akorn (AKRX) are up after the pharmaceutical company won U.S. antitrust approval to buy specialty prescription drug company VersaPharm.
Akorn Reports Preliminary 2014 Second Quarter Results
GlobeNewswire - Tue Aug 05, 5:36AM CDT
Akorn, Inc. (Nasdaq:AKRX), a niche generic pharmaceutical company, today reported preliminary financial results for the second quarter ended June 30, 2014.
Stocks Close Higher But Volume Declines
at Investor's Business Daily - Mon Aug 04, 3:19PM CDT
The stock market rebounded Monday, with the major indexes closing near session highs. The Nasdaq added 0.7% after the composite found support around its 50-day moving average. The S&P 500 also rose 0.7%, while the Dow Jones industrial average climbed...
Salix, Actavis Lead IBD 50 Drug Earnings This Week
at Investor's Business Daily - Sat Aug 02, 7:02AM CDT
Salix Pharmaceuticals (SLXP), which announced its tax inversion merger last month, will be among several IBD 50 drug stocks to report earnings this week. In July, Salix announced plans to merge with Italy's Cosmo Pharmaceuticals' Irish subsidiary,...
Akorn Shares Up 38.2% Since SmarTrend's Buy Recommendation (AKRX)
Comtex SmarTrend(R) - Thu Jul 31, 5:16PM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 3 months, Akorn has returned 38.21% as of today's recent price of $33.93.
Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva
M2 - Thu Jul 31, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l95k93/global) has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering. Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson's disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported. Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson's disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson's disease patients under certain circumstances. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by MOA 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Late-Stage Pipeline Candidates 18. Other Prominent Vendors 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Novartis AG - Teva Pharmaceutical Industries Ltd. - Abbvie Inc. - Akorn Inc. - Astellas Pharma Inc. - Desitin Arzneimittel GmbH - Endo International plc - F. Hoffmann-La Roche Ltd. - H. Lundbeck A/S - Kyowa Hakko Kirin - Merck & Co. Inc. - Orion Corp. - STADA Arzneimittel AG - UCB Inc. - US WorldMeds LLC - Valeant Pharmaceuticals International Inc. For more information visit http://www.researchandmarkets.com/research/l95k93/global
Uptrend Call Working As Akorn Stock Rises 41.5% (AKRX)
Comtex SmarTrend(R) - Thu Jul 24, 4:41PM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 3 months, Akorn has returned 41.47% as of today's recent price of $34.73.
Acasti Pharma (ACST) Jumps: Stock Moves 7.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:46AM CDT
Acasti Pharma (ACST) was a big mover last session, with shares rising over 7% on the day.
Uptrend Call Working As Akorn Stock Rises 35.7% (AKRX)
Comtex SmarTrend(R) - Thu Jul 17, 11:02AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 3 months, Akorn has returned 35.72% as of today's recent price of $33.32.
Market Losses Its Swagger In Afternoon Trade
at Investor's Business Daily - Wed Jul 16, 3:26PM CDT
Wednesday's stock market opened with a swagger, but closed with a stagger as it gave up a good chunk of a morning bounce. The Nasdaq rose 0.2%; the S&P 500 and the Dow Jones industrial average gained 0.4%. Volume was higher on the Nasdaq and lower on...
Stocks Recover From Early Fade; Whiting Hits New High
at Investor's Business Daily - Wed Jul 16, 12:35PM CDT
Stocks were again off their session highs but have regained some momentum. The Nasdaq, S&P 500 and Dow Jones industrial average were each up 0.4%. Earlier, the Nasdaq and S&P 500 retraced most of their morning gains. Turnover was again tracking mixed...
Adamas Pharmaceuticals, Inc. (ADMS) in Focus: Stock Rises 7.04% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:44AM CDT
Adamas Pharmaceuticals, Inc. (ADMS) was a big mover last session, as the company saw its shares rise 7% on the day.
Akorn, Inc. Announces Second Quarter 2014 Earnings Release and Conference Call Information
GlobeNewswire - Wed Jul 16, 3:52AM CDT
Akorn, Inc. (Nasdaq:AKRX) will host a conference call on Tuesday, August 5, 2014, to discuss second quarter 2014 results followed by a Q&A session. The company will release earnings the same day before the market opens.
Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 7:44AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) was a big mover last session, as the company saw its shares rise over 8% on the day.
Stocks Recover Impressively; Gap Slumps In After Hours
at Investor's Business Daily - Thu Jul 10, 4:22PM CDT
Major averages ended with modest losses Thursday, recovering impressively after an early sell-off. Wall Street was rattled early over newfound concerns about the health of European banks after Espirito Santo International, the parent company of...
Supernus Up on Non-Dilutive Royalty Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 3:43PM CDT
Supernus Pharmaceuticals, Inc.'s (SUPN) inked a non-dilutive royalty deal worth $30 million with HealthCare Royalty Partners.
Stocks Sag In Rising Trade; Archer Daniels And Avis Rise
at Investor's Business Daily - Tue Aug 05, 9:39AM CDT
Stocks stubbornly held their opening losses Tuesday, despite some strong factory orders and service-sector data. The Nasdaq and S&P 500 dipped 0.5% each. The Dow Jones industrial average slipped 3%. Small caps lagged the pack, with the Russell 2000...
Actavis Guidance Disappoints; Akorn Beats And Raises
at Investor's Business Daily - Tue Aug 05, 9:29AM CDT
Specialty drugmakers and IBD 50 stocks Actavis (ACT) and Akorn were headed in opposite directions in the stock market today after the companies reported their second-quarter earnings and updated their guidance. Actavis' earnings rose 70% over the...
Stock Futures Grope Lower; Gannett Surges On Plan To Split
at Investor's Business Daily - Tue Aug 05, 8:02AM CDT
Stock futures ticked lower early Tuesday as a weak services sector report out of China rattled China-based stocks in the U.S. Dow futures dived 66.3 points below fair market value and were still dropping. Nasdaq 100 futures were off a sharp 19.3...
Why Akorn (AKRX) Stock Is Advancing Today
at The Street - Tue Aug 05, 7:26AM CDT
Shares of Akorn (AKRX) are up after the pharmaceutical company won U.S. antitrust approval to buy specialty prescription drug company VersaPharm.
Akorn Reports Preliminary 2014 Second Quarter Results
GlobeNewswire - Tue Aug 05, 5:36AM CDT
Akorn, Inc. (Nasdaq:AKRX), a niche generic pharmaceutical company, today reported preliminary financial results for the second quarter ended June 30, 2014.
Stocks Close Higher But Volume Declines
at Investor's Business Daily - Mon Aug 04, 3:19PM CDT
The stock market rebounded Monday, with the major indexes closing near session highs. The Nasdaq added 0.7% after the composite found support around its 50-day moving average. The S&P 500 also rose 0.7%, while the Dow Jones industrial average climbed...
Salix, Actavis Lead IBD 50 Drug Earnings This Week
at Investor's Business Daily - Sat Aug 02, 7:02AM CDT
Salix Pharmaceuticals (SLXP), which announced its tax inversion merger last month, will be among several IBD 50 drug stocks to report earnings this week. In July, Salix announced plans to merge with Italy's Cosmo Pharmaceuticals' Irish subsidiary,...
Akorn Shares Up 38.2% Since SmarTrend's Buy Recommendation (AKRX)
Comtex SmarTrend(R) - Thu Jul 31, 5:16PM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 3 months, Akorn has returned 38.21% as of today's recent price of $33.93.
Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva
M2 - Thu Jul 31, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l95k93/global) has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering. Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson's disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported. Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson's disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson's disease patients under certain circumstances. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by MOA 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Late-Stage Pipeline Candidates 18. Other Prominent Vendors 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Novartis AG - Teva Pharmaceutical Industries Ltd. - Abbvie Inc. - Akorn Inc. - Astellas Pharma Inc. - Desitin Arzneimittel GmbH - Endo International plc - F. Hoffmann-La Roche Ltd. - H. Lundbeck A/S - Kyowa Hakko Kirin - Merck & Co. Inc. - Orion Corp. - STADA Arzneimittel AG - UCB Inc. - US WorldMeds LLC - Valeant Pharmaceuticals International Inc. For more information visit http://www.researchandmarkets.com/research/l95k93/global
Uptrend Call Working As Akorn Stock Rises 41.5% (AKRX)
Comtex SmarTrend(R) - Thu Jul 24, 4:41PM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 3 months, Akorn has returned 41.47% as of today's recent price of $34.73.
Acasti Pharma (ACST) Jumps: Stock Moves 7.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:46AM CDT
Acasti Pharma (ACST) was a big mover last session, with shares rising over 7% on the day.
Uptrend Call Working As Akorn Stock Rises 35.7% (AKRX)
Comtex SmarTrend(R) - Thu Jul 17, 11:02AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 3 months, Akorn has returned 35.72% as of today's recent price of $33.32.
Market Losses Its Swagger In Afternoon Trade
at Investor's Business Daily - Wed Jul 16, 3:26PM CDT
Wednesday's stock market opened with a swagger, but closed with a stagger as it gave up a good chunk of a morning bounce. The Nasdaq rose 0.2%; the S&P 500 and the Dow Jones industrial average gained 0.4%. Volume was higher on the Nasdaq and lower on...
Stocks Recover From Early Fade; Whiting Hits New High
at Investor's Business Daily - Wed Jul 16, 12:35PM CDT
Stocks were again off their session highs but have regained some momentum. The Nasdaq, S&P 500 and Dow Jones industrial average were each up 0.4%. Earlier, the Nasdaq and S&P 500 retraced most of their morning gains. Turnover was again tracking mixed...
Adamas Pharmaceuticals, Inc. (ADMS) in Focus: Stock Rises 7.04% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:44AM CDT
Adamas Pharmaceuticals, Inc. (ADMS) was a big mover last session, as the company saw its shares rise 7% on the day.
Akorn, Inc. Announces Second Quarter 2014 Earnings Release and Conference Call Information
GlobeNewswire - Wed Jul 16, 3:52AM CDT
Akorn, Inc. (Nasdaq:AKRX) will host a conference call on Tuesday, August 5, 2014, to discuss second quarter 2014 results followed by a Q&A session. The company will release earnings the same day before the market opens.
Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 7:44AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) was a big mover last session, as the company saw its shares rise over 8% on the day.
Stocks Recover Impressively; Gap Slumps In After Hours
at Investor's Business Daily - Thu Jul 10, 4:22PM CDT
Major averages ended with modest losses Thursday, recovering impressively after an early sell-off. Wall Street was rattled early over newfound concerns about the health of European banks after Espirito Santo International, the parent company of...
Supernus Up on Non-Dilutive Royalty Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 3:43PM CDT
Supernus Pharmaceuticals, Inc.'s (SUPN) inked a non-dilutive royalty deal worth $30 million with HealthCare Royalty Partners.
